SE9103397D0 - Nya substituerade salicylsyror - Google Patents

Nya substituerade salicylsyror

Info

Publication number
SE9103397D0
SE9103397D0 SE9103397A SE9103397A SE9103397D0 SE 9103397 D0 SE9103397 D0 SE 9103397D0 SE 9103397 A SE9103397 A SE 9103397A SE 9103397 A SE9103397 A SE 9103397A SE 9103397 D0 SE9103397 D0 SE 9103397D0
Authority
SE
Sweden
Prior art keywords
compound
new substituted
het
acids
substituted salicyl
Prior art date
Application number
SE9103397A
Other languages
English (en)
Swedish (sv)
Inventor
K H Agback
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9103397A priority Critical patent/SE9103397D0/xx
Publication of SE9103397D0 publication Critical patent/SE9103397D0/xx
Priority to NZ244998A priority patent/NZ244998A/en
Priority to AT92924067T priority patent/ATE194597T1/de
Priority to AU29589/92A priority patent/AU668528B2/en
Priority to EP92924067A priority patent/EP0613468B1/en
Priority to UA94005499A priority patent/UA42869C2/uk
Priority to SK547-94A priority patent/SK282080B6/sk
Priority to DK92924067T priority patent/DK0613468T3/da
Priority to DE69231252T priority patent/DE69231252T2/de
Priority to KR1019940701664A priority patent/KR100253748B1/ko
Priority to RU94028109A priority patent/RU2124501C1/ru
Priority to PCT/SE1992/000758 priority patent/WO1993010094A1/en
Priority to JP50919193A priority patent/JP3259915B2/ja
Priority to ES92924067T priority patent/ES2149780T3/es
Priority to CA002123697A priority patent/CA2123697C/en
Priority to HU9401391A priority patent/HU221476B/hu
Priority to IL10366592A priority patent/IL103665A/xx
Priority to US07/973,753 priority patent/US5302718A/en
Priority to LVP-92-202A priority patent/LV10246B/xx
Priority to MYPI92002100A priority patent/MY130169A/en
Priority to ZA928864A priority patent/ZA928864B/xx
Priority to PT101068A priority patent/PT101068B/pt
Priority to LTIP229A priority patent/LT3182B/lt
Priority to MX9206647A priority patent/MX9206647A/es
Priority to TW081109532A priority patent/TW304944B/zh
Priority to US08/132,874 priority patent/US5403930A/en
Priority to NO941799A priority patent/NO300805B1/no
Priority to FI942289A priority patent/FI106857B/fi
Priority to EE9400111A priority patent/EE03026B1/xx
Priority to US08/365,869 priority patent/US5556855A/en
Priority to HU95P/P00492P priority patent/HU211163A9/hu
Priority to GR20000402274T priority patent/GR3034585T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SE9103397A 1991-11-18 1991-11-18 Nya substituerade salicylsyror SE9103397D0 (sv)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
NZ244998A NZ244998A (en) 1991-11-18 1992-11-03 Heterocyclic substituted salicylic acid derivatives
KR1019940701664A KR100253748B1 (ko) 1991-11-18 1992-11-04 신규 치환된 살리실산
CA002123697A CA2123697C (en) 1991-11-18 1992-11-04 Novel substituted salicylic acids
HU9401391A HU221476B (en) 1991-11-18 1992-11-04 Substituted salicylic acid derivatives, pharmaceutical compositions comprising thereof and process for producing them
EP92924067A EP0613468B1 (en) 1991-11-18 1992-11-04 Substituted salicylic acids for the treatment of autoimmune diseases
UA94005499A UA42869C2 (uk) 1991-11-18 1992-11-04 Похідні саліцилової кислоти, спосіб одержання, фармацевтична композиція для лікування аутоімунного захворювання та спосіб лікування
SK547-94A SK282080B6 (sk) 1991-11-18 1992-11-04 Substituované salicylové kyseliny a ich použitie
DK92924067T DK0613468T3 (da) 1991-11-18 1992-11-04 Substituerede salicylsyrer til behandling af autoimmune sygdomme
DE69231252T DE69231252T2 (de) 1991-11-18 1992-11-04 Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten
AU29589/92A AU668528B2 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids
RU94028109A RU2124501C1 (ru) 1991-11-18 1992-11-04 Производные салициловой кислоты, их алкиловые эфиры, содержащие от 1 до 6 атомов углерода в эфирной группе, соли и сольваты
PCT/SE1992/000758 WO1993010094A1 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids
JP50919193A JP3259915B2 (ja) 1991-11-18 1992-11-04 新規な置換されたサリチル酸
ES92924067T ES2149780T3 (es) 1991-11-18 1992-11-04 Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes.
AT92924067T ATE194597T1 (de) 1991-11-18 1992-11-04 Substituierte salizylsäure zur behandlung von autoimmunkrankheiten
IL10366592A IL103665A (en) 1991-11-18 1992-11-06 Analogues of sulfasalazine and their use in the preparation of a medicament having therapeutic effect against autoimmune diseases
US07/973,753 US5302718A (en) 1991-11-18 1992-11-09 Compounds containing an amino salicylic acid moiety linked to a sulphapyridine moiety via stable bridge
LVP-92-202A LV10246B (en) 1991-11-18 1992-11-13 Novel substituted salicylic acids
MYPI92002100A MY130169A (en) 1991-11-18 1992-11-17 Novel substituted salicyclic acids
LTIP229A LT3182B (en) 1991-11-18 1992-11-17 Novel substituted salicylic acids
ZA928864A ZA928864B (en) 1991-11-18 1992-11-17 Substituted salicylic acids.
PT101068A PT101068B (pt) 1991-11-18 1992-11-17 Novos derivados do acido salicilico substituidos, seu processo de preparacao e composicoes farmaceuticas que os contem
MX9206647A MX9206647A (es) 1991-11-18 1992-11-18 Nuevos acidos salicilicos sustituidos.
TW081109532A TW304944B (cs) 1991-11-18 1992-11-27
US08/132,874 US5403930A (en) 1991-11-18 1993-10-07 Substituted salicylic acids
NO941799A NO300805B1 (no) 1991-11-18 1994-05-13 Nye substituerte salicylsyrer
FI942289A FI106857B (fi) 1991-11-18 1994-05-17 Menetelmä uusien farmakologisesti aktiivisten salisyylihappojohdannaisten valmistamiseksi
EE9400111A EE03026B1 (et) 1991-11-18 1994-11-02 Asendatud salitsüülhapped, meetod nende valmistamiseks ja nende kasutamine
US08/365,869 US5556855A (en) 1991-11-18 1994-12-29 N-heterocyclic substituted salicylic acids
HU95P/P00492P HU211163A9 (en) 1991-11-18 1995-06-28 Substituted salicylic acids
GR20000402274T GR3034585T3 (en) 1991-11-18 2000-10-09 Novel substituted salicyclic acids.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror

Publications (1)

Publication Number Publication Date
SE9103397D0 true SE9103397D0 (sv) 1991-11-18

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror

Country Status (29)

Country Link
US (3) US5302718A (cs)
EP (1) EP0613468B1 (cs)
JP (1) JP3259915B2 (cs)
KR (1) KR100253748B1 (cs)
AT (1) ATE194597T1 (cs)
AU (1) AU668528B2 (cs)
CA (1) CA2123697C (cs)
DE (1) DE69231252T2 (cs)
DK (1) DK0613468T3 (cs)
EE (1) EE03026B1 (cs)
ES (1) ES2149780T3 (cs)
FI (1) FI106857B (cs)
GR (1) GR3034585T3 (cs)
HU (2) HU221476B (cs)
IL (1) IL103665A (cs)
LT (1) LT3182B (cs)
LV (1) LV10246B (cs)
MX (1) MX9206647A (cs)
MY (1) MY130169A (cs)
NO (1) NO300805B1 (cs)
NZ (1) NZ244998A (cs)
PT (1) PT101068B (cs)
RU (1) RU2124501C1 (cs)
SE (1) SE9103397D0 (cs)
SK (1) SK282080B6 (cs)
TW (1) TW304944B (cs)
UA (1) UA42869C2 (cs)
WO (1) WO1993010094A1 (cs)
ZA (1) ZA928864B (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
CA2204616C (en) 1995-09-18 2002-12-17 Ranjan Mukherjee Ppar gamma antagonists for treating obesity
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
AU4676999A (en) 1998-06-12 1999-12-30 Ligand Pharmaceuticals, Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
WO2000056685A1 (en) 1999-03-19 2000-09-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
EP1214287B1 (en) 1999-09-04 2008-07-02 AstraZeneca AB Amides as inhibitors for pyruvate dehydrogenase
ES2273725T3 (es) 1999-09-04 2007-05-16 Astrazeneca Ab Derivados de hidroxiacetamidobencenosulfonamida.
BR0013694A (pt) 1999-09-04 2002-05-21 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
WO2001082907A2 (en) * 2000-04-28 2001-11-08 The University Of British Columbia Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100360342B1 (ko) * 2002-04-19 2002-11-13 박계정 밸런스 머신의 언밸런스 수정위치 및 수정량의 자동 보상방법
US7732442B2 (en) * 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
EP1991530A1 (en) * 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
MX2010014232A (es) * 2008-06-23 2011-03-25 Astellas Pharma Inc Compuesto de sulfamida o sal del mismo.
CN103547152A (zh) * 2011-02-23 2014-01-29 西奈山伊坎医学院 溴结构域蛋白的抑制剂作为基因表达的调节剂
NZ737004A (en) 2015-05-20 2022-10-28 Amgen Inc Triazole agonists of the apj receptor
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
LTIP229A (en) 1994-09-25
IL103665A0 (en) 1993-04-04
WO1993010094A1 (en) 1993-05-27
PT101068A (pt) 1994-02-28
EP0613468A1 (en) 1994-09-07
DE69231252D1 (de) 2000-08-17
CA2123697C (en) 2003-12-09
US5302718A (en) 1994-04-12
HU211163A9 (en) 1995-10-30
FI942289A0 (fi) 1994-05-17
GR3034585T3 (en) 2001-01-31
US5556855A (en) 1996-09-17
DE69231252T2 (de) 2001-03-01
AU2958992A (en) 1993-06-15
ATE194597T1 (de) 2000-07-15
JP3259915B2 (ja) 2002-02-25
EP0613468B1 (en) 2000-07-12
LV10246B (en) 1995-04-20
EE03026B1 (et) 1997-08-15
HU221476B (en) 2002-10-28
NO941799D0 (no) 1994-05-13
NO300805B1 (no) 1997-07-28
RU2124501C1 (ru) 1999-01-10
SK282080B6 (sk) 2001-10-08
PT101068B (pt) 1999-08-31
LV10246A (lv) 1994-10-20
HUT69723A (en) 1995-09-28
UA42869C2 (uk) 2001-11-15
ES2149780T3 (es) 2000-11-16
SK54794A3 (en) 1995-02-08
IL103665A (en) 1997-08-14
KR100253748B1 (ko) 2000-05-01
HU9401391D0 (en) 1994-08-29
TW304944B (cs) 1997-05-11
NO941799L (cs) 1994-06-22
DK0613468T3 (da) 2000-10-23
FI106857B (fi) 2001-04-30
FI942289L (fi) 1994-05-17
JPH07501330A (ja) 1995-02-09
CA2123697A1 (en) 1993-05-27
NZ244998A (en) 1995-09-26
ZA928864B (en) 1993-05-13
AU668528B2 (en) 1996-05-09
US5403930A (en) 1995-04-04
MX9206647A (es) 1993-05-01
LT3182B (en) 1995-03-27
MY130169A (en) 2007-06-29

Similar Documents

Publication Publication Date Title
SE9103397D0 (sv) Nya substituerade salicylsyror
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
DK0638071T3 (da) Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
FI954609A0 (fi) 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina
ATE114670T1 (de) Phenylamidinderivate als plättchenaggregationsinhibitoren.
AR058180A1 (es) Indeno derivados, su preparacion y su uso como medicamentos
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
AR004670A1 (es) Compuestos derivados de acido amino sustituido arilo y heteroarilo carboxilico; composicion farmaceutica que los contiene; metodo para aliviar eldolor; procedimiento para preparar dichos compuestos y compuestos utiles como material de partida
FI940414A0 (fi) Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
ATE157088T1 (de) Neue chinolon- und naphthyridoncarbonsäurederivate
ATE161017T1 (de) Inhibitoren gegen die aggregation von blutplättchen
NZ505614A (en) Pentasaccharides and pharmaceutical compositions thereof, useful as anti blood clotting agnets
UA41350C2 (uk) Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
NO305799B1 (no) Nye kinolinderivater, farmas°ytiske preparater inneholdende slike derivater, deres anvendelse samt mellomprodukter
ATE202773T1 (de) Neue polycyclische phthalazinderivate und ihre verwendung
ATE361307T1 (de) Neue arzneimittel